Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E8.73 EPS (ttm)27.00 Insider Own0.10% Shs Outstand190.30M Perf Week1.42%
Market Cap44.84B Forward P/E7.34 EPS next Y32.10 Insider Trans181.48% Shs Float183.64M Perf Month1.88%
Income5.32B PEG1.92 EPS next Q8.22 Inst Own91.60% Short Float2.14% Perf Quarter0.28%
Sales14.07B P/S3.19 EPS this Y24.50% Inst Trans-5.43% Short Ratio2.74 Perf Half Y3.85%
Book/sh68.07 P/B3.46 EPS next Y-0.30% ROA20.50% Target Price258.33 Perf Year-30.06%
Cash/sh15.51 P/C15.19 EPS next 5Y4.56% ROE39.50% 52W Range215.77 - 358.41 Perf YTD-21.70%
Dividend- P/FCF6.68 EPS past 5Y22.70% ROI23.60% 52W High-34.26% Beta1.02
Dividend %- Quick Ratio2.20 Sales past 5Y14.20% Gross Margin85.60% 52W Low9.20% ATR5.49
Employees7800 Current Ratio2.50 Sales Q/Q7.80% Oper. Margin46.90% RSI (14)54.98 Volatility2.33% 2.34%
OptionableYes Debt/Eq0.00 EPS Q/Q87.70% Profit Margin37.60% Rel Volume0.86 Prev Close235.17
ShortableYes LT Debt/Eq0.46 EarningsOct 22 BMO Payout0.00% Avg Volume1.43M Price235.62
Recom2.90 SMA203.35% SMA501.44% SMA200-10.99% Volume1,260,814 Change0.19%
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Sep-19-19 11:30AM  Biogen's New Study to Test Higher Dose of SMA Drug Spinraza Zacks
07:17AM  Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 Zacks
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
10:04AM  Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis Zacks
07:30AM  Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients GlobeNewswire
Sep-17-19 04:05PM  6 Undervalued Companies Growing Earnings
07:30AM  Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index GlobeNewswire
Sep-16-19 11:49AM  This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal Investor's Business Daily
11:30AM  S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels PR Newswire
10:17AM  The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors Zacks
10:16AM  Biogen Stops Late-Stage Studies on Alzheimer's Candidate Zacks
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-13-19 04:18PM  Biogen Scraps 2 More Studies In Alzheimer's Disease And Shares Pop Investor's Business Daily
11:00AM  Biogen Scraps 2 More Studies In Alzheimer's Disease And Shares Pop Investor's Business Daily
10:05AM  Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs American City Business Journals
08:44AM  UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment Reuters
08:42AM  What September Doldrums? Here's Why Stocks Are Moving Higher Zacks
08:18AM  Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment MarketWatch
08:13AM  Biogen scraps two late-stage Alzheimer's trials Reuters
08:00AM  Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease PR Newswire
07:45AM  Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate Zacks
05:32AM  Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials
Sep-12-19 03:15PM  Does Biogen Inc.'s (NASDAQ:BIIB) CEO Pay Matter? Simply Wall St.
05:00AM  New Research Demonstrate Biogens Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum GlobeNewswire
Sep-11-19 07:09AM  The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
05:00AM  New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years GlobeNewswire
Sep-09-19 10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks
Sep-08-19 05:09PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 6
Sep-05-19 05:01PM  6 Stocks With Low Price-Sales Ratios
08:05AM  5 Price-to-Book Value Picks for September Zacks
Sep-04-19 10:17AM  Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals
09:37AM  Novartis Inks Commercialization Deal for Tysabri Biosimilar Zacks
Sep-01-19 07:00AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Aug-30-19 08:04AM  Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies Zacks
Aug-28-19 02:15PM  Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks
08:51AM  5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market Zacks
Aug-25-19 02:00PM  Better Buy: Biogen vs. Celgene Motley Fool
Aug-24-19 05:46PM  Stocks That Fell to 3-Year Lows in the Week of Aug. 23
Aug-21-19 07:10AM  Could The Biogen Inc. (NASDAQ:BIIB) Ownership Structure Tell Us Something Useful? Simply Wall St.
06:00AM  Biogen- Buybacks and Biotech MoneyShow
Aug-20-19 07:30AM  Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients GlobeNewswire
Aug-19-19 08:04AM  AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA Zacks
Aug-14-19 09:35AM  Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? Zacks
09:10AM  Are Investors Undervaluing Biogen (BIIB) Right Now? Zacks
Aug-13-19 10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
Aug-12-19 09:09AM  Top Ranked Momentum Stocks to Buy for August 12th Zacks
08:59AM  5 ROE Stocks to Profit as Trade War Spurs Volatility Zacks
Aug-08-19 10:17AM  PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y Zacks
09:26AM  Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks
Aug-07-19 07:54PM  Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy American City Business Journals
06:45AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Aug-06-19 04:47PM  Edited Transcript of BIIB earnings conference call or presentation 23-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
04:22PM  Biotech ETFs in Focus on Impressive Q2 Earnings Results Zacks
Aug-02-19 12:20PM  Top Ranked Momentum Stocks to Buy for August 2nd Zacks
06:04AM  5 years later, Ice Bucket Challenge's impact on drug research still unfolding American City Business Journals
05:00AM  Biogen on the brink: One of the state's largest drugmakers faces a crisis American City Business Journals
Aug-01-19 09:15AM  Stocks Advance in July Despite Rate Cut Selloff Zacks
06:00AM  Biogen- A Biotech Buyback Bet MoneyShow
01:00AM  Long-Term Outperformance Is the Norm at This Large-Cap Fund Morningstar
Jul-31-19 12:00PM  Top Ranked Momentum Stocks to Buy for July 31st Zacks
07:11AM  Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly Simply Wall St.
Jul-30-19 03:05PM  Biogen Hedged Its Bet and Won Big Motley Fool
08:45AM  3 Reasons Growth Investors Will Love Biogen (BIIB) Zacks
08:00AM  The 5 Worst S&P 500 Stocks Are Costing You $22.3 Billion; Here's Why Investor's Business Daily
07:30AM  Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis GlobeNewswire
Jul-29-19 10:32AM featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman Zacks
Jul-26-19 01:45PM  Alkermes Bounces Back -- but Not Enough Motley Fool
12:00PM  AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling.
10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
08:20AM  Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility Zacks
Jul-25-19 02:58PM  Top Analyst Reports for Texas Instruments, Blackstone & Northrop Grumman Zacks
Jul-24-19 03:31PM  Biogen Raises Guidance as It Looks to the Pipeline for Growth Motley Fool
10:58AM  Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks
07:15AM  Celgene, Bristol-Myers and AbbVie still to report earnings this week: Heres what to expect MarketWatch
Jul-23-19 04:41PM  Biogen Earnings Crush Forecasts; But Pay Attention To These Two Elements Investor's Business Daily
02:43PM  Biogen tops earnings expectations, but still has some longer-term issues to address MarketWatch
01:23PM  Biogen Inc (BIIB) Q2 2019 Earnings Call Transcript Motley Fool
11:42AM  Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat InvestorPlace
10:42AM  Biogen downplays premature talk of competition for SMA drug Spinraza American City Business Journals
10:16AM  Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View Zacks
09:56AM  Biogens Good Quarter Delays Drugmakers Future Reckoning Bloomberg
08:56AM  Biogen (BIIB) Q2 Earnings & Sales Beat Estimates Zacks
08:39AM  Biogens Earnings Beat Forecasts, but 1 Key Drug Fell Short
08:01AM  The Fed cant stop a market meltdown, warns forecaster who called the 2008 housing bust MarketWatch
07:29AM  US STOCKS-Futures rise after better-than-expected earnings Reuters
07:26AM  The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga
07:11AM  Biotech group Biogen boosted by sales of key drugs Financial Times
06:58AM  UPDATE 3-Multiple sclerosis drug helps Biogen beat Wall St profit expectations Reuters
06:45AM  Biogen's stock jumps after big earnings beat, raised outlook MarketWatch
06:39AM  Biogen profit rises 72% Reuters
05:36AM  Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost
04:34AM  Stocks - Lockheed Martin, Hasbro, Coca-Cola, Starbucks Rise Premarket
02:47AM  Biogen Earnings, Revenue Beat in Q2
Jul-22-19 04:09PM  Biogen Earnings: Here's What Investors Are Hoping To See In Report Investor's Business Daily
01:58PM  MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock InvestorPlace
Jul-20-19 09:53AM  The Week Ahead In Biotech: Pharma Earnings Pick Up Pace Benzinga
Jul-19-19 09:35AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks
Jul-17-19 03:22PM  The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On Motley Fool
Jul-16-19 02:14PM  Eisai boosts focus on Alzheimer's with new research facility, funding American City Business Journals
10:31AM  Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM